The new addition brings a small conglomerate spread across eight cities, mostly concentrated on the east coast of the United States.
BOSTON, June 28, 2022 /PRNewswire-PRWeb/ -- hyperCORE International is excited to welcome Alcanza Clinical Research to its super network of clinical trial sites as the organization continues expanding their reach and capabilities across the clinical research arena.
Alcanza Clinical Research was founded in December 2021 with the goal of establishing an inclusive clinical research environment to rapidly expand participation from underrepresented patient populations across different minority groups, genders, sexual orientations, disability statuses, and more. It has acquired four high-performing research brands (including Boston Clinical Trials, ActivMed/Allcutis, Quest Research Institute, and Coastal Carolina Research Center) across eight locations in Michigan, Massachusetts, New Hampshire, and South Carolina. Each brand brings 20 to 25 years of experience in clinical research and complementary specializations in chronic conditions and infectious diseases. Alcanza's therapeutic and geographic expansion plans will focus on achieving its namesake mission (to reach) and creating a sustainable clinical trial environment for all.
"Alcanza Clinical Research is another exciting addition to hyperCORE International," said Karri Venn, CEO. "Although, the formation of Alcanza is new, the members are incredibly aligned in expertise and strategic vision, which will allow them to elevate and grow the number of professional sites we can offer to our industry partners in a streamlined and efficient manner."
The partnership with Alcanza's clinical trial network represents an approximate 10% growth for hyperCORE, and brings expanded capabilities in Neurology, Psychiatry, Dermatology, and Infectious Disease. This further strengthens its position as a premier provider of clinical trial services.
"Alcanza's leadership team understands the power of a site network. hyperCORE is the right partner for Alcanza, and the time is now," stated Alcanza CEO Carlos Orantes. "The individual companies associated with this group are industry leaders and as a collective group make an even stronger value proposition for all clients working with us. We look forward to collaborating with all member companies to share and apply best practices. Together, we will create an even stronger offering to the clinical research community to advance next-generation therapies."
About hyperCORE International:
Formed in 2019, hyperCORE International is a super network of highly experienced and awarded clinical research site/network companies. It is an industry leader, providing Phase I-IV clinical trial services with more than 100 active research sites on two continents and five countries. Each of its alliance partners have decades of clinical research experience and have collectively completed more than 7,000 studies helping to evaluate thousands of new drugs and treatments in more than 140,000 randomized patients. Each partner operates as an independent company but integrates common functions to streamline business and clinical operations through harmonization and sharing of best practices.
hyperCORE International is committed to the highest standard of research excellence with subject safety, data integrity, rapid study startup, competitive enrollment, and outstanding subject retention as top priorities. Its members have won numerous awards for performance, quality, and innovation.
Media Contact
Michael Casey, hyperCORE International, 1 9193024090, mcasey@hypercoreinternational.com
SOURCE hyperCORE International
Share this article